Table 3.
Identification of Independent Prognostic Factors for OS in All-Patient, the TACE Group, and the TACE-Sorafenib Group Based on Multivariate Cox Regression
| Baseline Factor | All-Patient | TACE Group | TACE-Sorafenib Group | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Treatment (T+S vs T) | 0.30 (0.19–0.47) | <0.001 | — | — | — | — |
| No. of tumors | — | — | — | — | — | — |
| 2–3 vs.1 | 0.97 (0.39–2.41) | 0.948 | 2.35 (0.81–6.83) | 0.116 | — | — |
| ≥ 4 vs.1 | 2.32 (1.35–3.98) | 0.002 | 3.09 (1.38–6.89) | 0.006 | — | — |
| PVTT (Yes vs No) | 2.07 (1.18–3.65) | 0.012 | 3.56 (1.49–8.53) | 0.004 | — | — |
| EHS (Yes vs No) | 2.49 (1.43–4.34) | 0.001 | 3.65 (1.56–8.59) | 0.003 | 2.42 (1.27–4.58) | 0.007 |
| AFP (> vs ≤400ng/mL) | 1.78 (1.12–2.82) | 0.014 | — | — | 2.85 (1.50–5.43) | 0.001 |
| Tbil (> vs ≤17.5μmol/L) | — | — | — | — | 2.03 (1.07–3.86) | 0.031 |
| ALP (> vs ≤122.5U/L) | 1.81 (1.15–2.86) | 0.011 | — | — | 2.46 (1.31–4.64) | 0.005 |
| VEGF (> vs ≤172.48pg/mL) | 1.95 (1.26–3.02) | 0.003 | 2.21 (1.19–4.13) | 0.013 | 1.92 (1.02–3.61) | 0.044 |
Abbreviations: T+S, TACE plus sorafenib; PVTT, portal vein tumor thrombus; EHS, extrahepatic spread; AFP, alpha-fetoprotein; Tbil, total bilirubin; ALP, alkaline phosphatase; VEGF, vascular endothelial growth factor.